With fewer than 1 in 4 patients with cirrhosis surveilled for HCC, the American Gastroenterological Association (AGA) has ...
Perioperative immunotherapy improves hepatocellular carcinoma outcomes, reducing recurrence risk and enhancing event free ...
Long-term use of statins may delay or deflect the development of hepatocellular carcinoma in adults with chronic liver disease, as well as in the general population, emerging research, including ...
Hepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide, with limited curative options. Tumor vaccines ...
Real-World Utilization and Performance of Circulating Tumor DNA Monitoring to Predict Recurrence in Solid Tumors Hepatocellular carcinoma (HCC) has an increasing incidence and global mortality burden.
Dr. David M. Dudzinski: A 59-year-old man with a history of obesity, dyslipidemia, and hypertension was evaluated in the oncology clinic of this hospital because of hepatocellular carcinoma.
Efficacy and safety of donafenib combined with PD-(L)1 inhibitors plus TACE for unresectable hepatocellular carcinoma patients. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results